{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bipolar+Disorder+Moderate",
    "query": {
      "condition": "Bipolar Disorder Moderate"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T07:37:25.983Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04211428",
      "title": "A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bipolar Disorder",
        "Bipolar I Disorder",
        "Bipolar II Disorder",
        "Bipolar Type I Disorder",
        "Bipolar Disorder Mild",
        "Bipolar Disorder Moderate",
        "Bipolar Disorder Severe"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "ProgenaBiome",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2020-03-02",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-07-22T07:37:25.983Z",
      "location_count": 1,
      "location_summary": "Ventura, California",
      "locations": [
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04211428"
    },
    {
      "nct_id": "NCT00167479",
      "title": "A Study of Risperidone Monotherapy in Bipolar Anxiety",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Panic Disorder",
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "risperidone (Risperdal)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2003-09",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2006-09-11",
      "last_synced_at": "2026-07-22T07:37:25.983Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Cincinnati, Ohio • Dallas, Texas",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00167479"
    },
    {
      "nct_id": "NCT00277667",
      "title": "Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Quetiapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lindner Center of HOPE",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2004-02",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2009-03-13",
      "last_synced_at": "2026-07-22T07:37:25.983Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00277667"
    },
    {
      "nct_id": "NCT03402152",
      "title": "NRX101 Glx Biomarker Validation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Depression",
        "Suicidal Ideation"
      ],
      "interventions": [
        {
          "name": "NRX-101",
          "type": "DRUG"
        },
        {
          "name": "Lurasidone HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeuroRx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 8,
      "start_date": "2018-11-01",
      "completion_date": "2021-06-01",
      "has_results": false,
      "last_update_posted_date": "2022-08-09",
      "last_synced_at": "2026-07-22T07:37:25.983Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03402152"
    },
    {
      "nct_id": "NCT05064319",
      "title": "Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Cannabis Use",
        "Schizoaffective Disorder, Bipolar Type",
        "Bipolar I Disorder",
        "Bipolar II Disorder",
        "Cannabis Use Disorder, Mild",
        "Cannabis Use Disorder, Moderate",
        "Cannabis Use Disorder, Severe"
      ],
      "interventions": [
        {
          "name": "Gabapentin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 68,
      "start_date": "2022-02-24",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-07-22T07:37:25.983Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05064319"
    },
    {
      "nct_id": "NCT00277654",
      "title": "Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lindner Center of HOPE",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2004-02",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2011-12-13",
      "last_synced_at": "2026-07-22T07:37:25.983Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00277654"
    },
    {
      "nct_id": "NCT00094549",
      "title": "Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "divalproex sodium",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 500,
      "start_date": "2004-10",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2007-01-26",
      "last_synced_at": "2026-07-22T07:37:25.983Z",
      "location_count": 31,
      "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Costa Mesa, California + 28 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00094549"
    },
    {
      "nct_id": "NCT00579280",
      "title": "Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Panic Disorder",
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "quetiapine SR",
          "type": "DRUG"
        },
        {
          "name": "divalproex sodium ER",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 224,
      "start_date": "2007-07",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2020-06-11",
      "last_synced_at": "2026-07-22T07:37:25.983Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • Tampa, Florida • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00579280"
    },
    {
      "nct_id": "NCT06093451",
      "title": "Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia Agitation",
        "Schizo Affective Disorder",
        "Bipolar Disorder",
        "Dexmedetomidine"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Lorazepam 2 MG/ML",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Temple University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2023-07-01",
      "completion_date": "2024-07-01",
      "has_results": false,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-07-22T07:37:25.983Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06093451"
    },
    {
      "nct_id": "NCT00278772",
      "title": "Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomania or Mild Mania",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Spectrum Disorder With Moderate-to- Severe Hypomania or Mild Mania"
      ],
      "interventions": [
        {
          "name": "Divalproex",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Lindner Center of HOPE",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2003-08",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2010-05-26",
      "last_synced_at": "2026-07-22T07:37:25.983Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00278772"
    }
  ]
}